Payment overview · 2025
General Payments
$470.63
18 reported records · 11 companies
Healthcare provider profile · identity verified
Thomas Tung Ching Chen, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LAS VEGAS, NV · NPI 1992875538
Verified facts
What the public records show
CMS Open Payments records show Thomas Tung Ching Chen, M.D. received $470.63 in general payments during 2025 across 18 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 25.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $121.96 | 25.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $79.41 | 16.9% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $53.46 | 11.4% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $48.45 | 10.3% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $32.75 | 7.0% | 2 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.19 | 5.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.01 | 5.5% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.20 | 4.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.98 | 4.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.47 | 4.3% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $17.75 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $470.63 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $79.41 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $79.41 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $79.41 | 4 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $48.45 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $44.12 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $32.75 | 2 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $26.19 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $22.20 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.98 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $21.98 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.47 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.47 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.64 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.64 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $17.75 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $15.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
46 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
46 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 708 | 196 |
| Atorvastatin Calcium | Atorvastatin Calcium | 522 | 166 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 521 | 151 |
| Losartan Potassium | Losartan Potassium | 459 | 130 |
| Lisinopril | Lisinopril | 332 | 97 |
| Metformin Hcl Er | Metformin Hcl | 318 | 93 |
| Levothyroxine Sodium | Levothyroxine Sodium | 303 | 77 |
| Pravastatin Sodium | Pravastatin Sodium | 265 | 73 |
| Tamsulosin Hcl | Tamsulosin Hcl | 197 | 56 |
| Omeprazole | Omeprazole | 175 | 43 |
| Simvastatin | Simvastatin | 173 | 48 |
| Alprazolam | Alprazolam | 143 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 136 | 46 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 129 | 35 |
| Metformin Hcl | Metformin Hcl | 129 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 128 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 124 | 37 |
| Allopurinol | Allopurinol | 107 | 30 |
| Gabapentin | Gabapentin | 103 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 100 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 87 | 26 |
| Benazepril Hcl | Benazepril Hcl | 86 | 24 |
| Carvedilol | Carvedilol | 86 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 80 | 28 |
| Atenolol | Atenolol | 78 | 24 |
| Trazodone Hcl | Trazodone Hcl | 78 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 21 |
| Lovastatin | Lovastatin | 70 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 68 | 16 |
| Finasteride | Finasteride | 65 | 15 |
| Potassium Chloride | Potassium Chloride | 61 | 22 |
| Glimepiride | Glimepiride | 60 | 18 |
| Alendronate Sodium | Alendronate Sodium | 59 | 19 |
| Meloxicam | Meloxicam | 56 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 56 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 54 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 54 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 17 |
| Montelukast Sodium | Montelukast Sodium | 48 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 30 |
| Eliquis | Apixaban | 46 | 18 |
| Ezetimibe | Ezetimibe | 46 | 20 |
| Jardiance | Empagliflozin | 43 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 43 | suppressed |
| Valsartan | Valsartan | 42 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 12 |
| Temazepam | Temazepam | 41 | suppressed |
| Trulicity | Dulaglutide | 41 | suppressed |
| Famotidine | Famotidine | 40 | 15 |
| Furosemide | Furosemide | 40 | 16 |
| Glipizide | Glipizide | 39 | 13 |
| Lorazepam | Lorazepam | 37 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 36 | suppressed |
| Baclofen | Baclofen | 33 | suppressed |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 32 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Ramipril | Ramipril | 30 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 29 | suppressed |
| Ibuprofen | Ibuprofen | 28 | 13 |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 25 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Ibu | Ibuprofen | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Ozempic | Semaglutide | 19 | suppressed |
| Novolog | Insulin Aspart | 18 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $470.63 · 18 records | E.R. Squibb & Sons, L.L.C. | ABRYSVO, AREXVY, COMIRNATY, EDARBI, Flucelvax, JARDIANCE, KISUNLA, MOUNJARO, NEXLETOL, OTEZLA, PREVNAR 20, PYRUKYND, REPATHA, SHINGRIX, ZEPBOUND, ZORYVE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error